Daily Cosmetic Research Analysis
Analyzed 16 papers and selected 3 impactful papers.
Summary
Across aesthetic and reconstructive domains, one randomized trial supports a scar-concealing axillary endoscopic thyroidectomy with equivalent early oncologic outcomes and better patient-reported recovery. A mechanistic biomaterials study identifies MYBL2 as a key transcriptional node through which PHA microspheres promote collagen synthesis and skin regeneration. A meta-analysis of randomized trials confirms onabotulinumtoxinA effectively and safely improves platysma neck bands.
Research Themes
- Minimally invasive and scar-concealing surgical approaches
- Biomaterials-driven skin rejuvenation via defined transcriptional mechanisms
- Evidence synthesis for aesthetic neuromodulators
Selected Articles
1. Safety and Efficacy of Endoscopic Thyroidectomy by Gasless Unilateral Axillary for Papillary Thyroid Carcinoma in Primary Hospitals.
In a single-center randomized trial of 196 patients with papillary thyroid carcinoma, gasless unilateral axillary endoscopic thyroidectomy achieved comparable 1-year oncologic metrics to open surgery, with less blood loss, shorter hospitalization, lower pain, and higher cosmetic satisfaction despite longer operative time. Performance stabilized after 30–40 cases, indicating a moderate learning curve.
Impact: Provides randomized evidence that a scar-concealing axillary approach can maintain early oncologic rigor while improving patient-centered outcomes. This supports broader adoption in resource-limited primary hospitals with appropriate training.
Clinical Implications: ETGUA can be offered to suitable PTC patients seeking better cosmetic outcomes without compromising short-term oncologic control; programs should anticipate a 30–40 case learning curve and slightly higher costs.
Key Findings
- ETGUA had longer operative time but less intraoperative blood loss and shorter postoperative hospital stay than open surgery (p<0.05).
- At 1 year, oncologic indicators (lymph nodes dissected/positive, sTg, RAI use) were comparable between groups (p>0.05).
- ETGUA yielded lower VAS pain scores and higher cosmetic satisfaction but slightly higher total hospitalization cost (p<0.05).
- Learning curve analysis showed operative metrics stabilized after approximately 30–40 cases.
Methodological Strengths
- Prospective randomized controlled design with predefined surgical and oncologic outcomes
- Comprehensive perioperative assessment including pain and cosmetic satisfaction, plus learning-curve analysis
Limitations
- Single-center study with 1-year oncologic follow-up limits generalizability and long-term cancer control assessment
- Lack of blinding and slightly higher costs may influence perceived benefits and adoption
Future Directions: Multi-center, longer-term RCTs comparing disease-free/overall survival and quality-of-life, with cost-effectiveness analyses and training standardization.
OBJECTIVE: To compare the safety and surgical efficacy of endoscopic thyroidectomy by gasless unilateral axillary (ETGUA) with conventional open thyroidectomy in patients with papillary thyroid carcinoma (PTC). METHODS: This prospective, single-center, and randomized controlled trial included 196 patients with PTC who met the inclusion and exclusion criteria. Patients were randomly assigned in a 1:1 ratio to the ETGUA group (n = 98) or the open thyroidectomy group (n = 98). Complications within 30 days, parathyroid function [intact parathyroid hormone (iPTH) and serum calcium], and short-term oncological outcomes were observed. Secondary outcomes included operative time, intraoperative blood loss, postoperative recovery, pain score, cosmetic satisfaction, and hospitalization cost. RESULTS: The ETGUA group had a significantly longer operative time than the open thyroidectomy group, less intraoperative blood loss, more postoperative drainage at postoperative day 1, as well as a shorter postoperative hospital stay (all p < 0.05). At 1 year postoperatively, surgical efficacy and oncological indicators such as the number of lymph nodes dissected, number of positive lymph nodes, stimulated thyroglobulin (sTg) level, and the proportion of patients receiving adjuvant radioactive iodine therapy were comparable between groups (p > 0.05). The ETGUA group reported lower visual analog scale (VAS) pain scores and higher cosmetic satisfaction, though the total hospitalization cost was slightly higher (all p < 0.05). The learning curve analysis indicated that operative time and intraoperative blood loss stabilized after approximately 30-40 cases. CONCLUSION: ETGUA demonstrates comparable safety and oncological efficacy to conventional open thyroidectomy in PTC patients.
2. Polyhydroxyalkanoate Microspheres Promote Skin Regeneration by Activating the MYBL2 Transcription Factor.
Using in vitro human fibroblasts and an in vivo rat model, PHA microspheres increased epidermal thickness and collagen I/III expression while enhancing mitochondrial ATP production. Mechanistically, MYBL2 was necessary for PHA-induced fibroblast proliferation and collagen synthesis, defining a transcriptional pathway for biomaterial-driven skin regeneration.
Impact: Identifies MYBL2 as a required transcriptional regulator linking biomaterial stimulation to fibroblast proliferation and collagen production, advancing mechanistic understanding of skin rejuvenation strategies.
Clinical Implications: Supports the development of PHA microspheres as collagen stimulators for aesthetic dermatology and regenerative indications; human trials should evaluate dosing, durability, and long-term safety.
Key Findings
- PHA microspheres increased epidermal thickness and collagen I/III expression in vivo while promoting human fibroblast proliferation in vitro.
- Mitochondrial function improved with elevated ATP production following PHA microsphere exposure.
- MYBL2 knockdown abrogated PHA-induced proliferation, collagen synthesis, and mitochondrial enhancement, establishing MYBL2 as necessary for regeneration.
- Systemic safety was demonstrated in a rat model, indicating favorable biocompatibility.
Methodological Strengths
- Mechanistic interrogation with gene knockdown establishes necessity of MYBL2
- Convergent in vitro and in vivo evidence including mitochondrial functional assays and histology
Limitations
- Preclinical study without human clinical outcomes or long-term durability data
- Dose-response optimization and comparative efficacy versus existing biostimulators are not defined
Future Directions: Phase I/II clinical trials to establish safety, dosing, and durability; exploration of MYBL2-targeted combination strategies and indication expansion to scars and wound healing.
Fibroblast-mediated decreased collagen synthesis is a key aspect of skin aging. Polyhydroxyalkanoate (PHA) materials have established clinical biocompatibility; however, the direct mechanisms of PHA microspheres on fibroblast-mediated skin rejuvenation remain unexplored. We aimed to investigate the impact of PHA microspheres on collagen production and its underlying molecular pathways. The microspheres demonstrated high biocompatibility, promoting human fibroblast proliferation in vitro and showing robust systemic safety in a rat model. In vivo, PHA microsphere injection significantly increased epidermal thickness and the expression of collagen I and III. Mechanistically, PHA microspheres improved mitochondrial function, as evidenced by elevated ATP production. MYBL2 was identified as a key transcriptional regulator; its knockdown attenuated fibroblast proliferation, collagen synthesis, and mitochondrial function. Importantly, PHA stimulation failed to rescue this effect, confirming that MYBL2 is required for the observed regeneration. In summary, we demonstrate that PHA microspheres drive fibroblast proliferation and collagen synthesis by upregulating MYBL2 and enhancing mitochondrial function. These findings provide a theoretical basis for the application of PHA microspheres as a collagen stimulant for skin rejuvenation.
3. Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Platysma Prominence: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Across three RCTs (n=912), onabotulinumtoxinA significantly improved platysma prominence by clinician- and patient-rated scales with no increase in adverse events. Patient satisfaction was substantially higher, supporting standardized use for aesthetic neck bands.
Impact: Synthesizes randomized evidence demonstrating robust efficacy and tolerability of onabotulinumtoxinA for neck bands, informing practice and patient counseling.
Clinical Implications: Supports adopting onabotulinumtoxinA for moderate–severe platysma prominence using validated scales, with expectations of meaningful aesthetic gains and similar TEAE rates to placebo.
Key Findings
- OnabotulinumtoxinA increased ≥1-grade (RR 4.11) and ≥2-grade (RR 1.83) improvements on Allergan Platysma Prominence Scales versus placebo.
- Patient satisfaction was markedly higher with treatment (RR 5.55).
- Treatment-emergent adverse events were similar to placebo (RR 0.95) and mostly mild and transient.
Methodological Strengths
- Meta-analysis restricted to RCTs with dual independent data extraction and Cochrane RoB 2.0 bias assessment
- Use of validated clinician and participant aesthetic outcome scales and random-effects modeling
Limitations
- Only three RCTs included; heterogeneity and long-term durability beyond trial follow-up are unclear
- Procedure techniques and dosing regimens may vary across trials, limiting protocol standardization
Future Directions: Head-to-head dosing and technique trials with longer follow-up, patient-reported outcome standardization, and real-world safety registries.
BACKGROUND: Platysma prominence (PP) is a common aesthetic concern associated with aging, leading to visible neck bands and loss of jawline definition. OnabotulinumtoxinA has emerged as a minimally invasive treatment; however, data from randomized controlled trials (RCTs) remain fragmented. AIMS: To systematically evaluate the efficacy and safety of onabotulinumtoxinA for treating moderate to severe PP through meta-analysis of RCTs. METHODS: PubMed, Cochrane CENTRAL, and ClinicalTrials.gov were searched from inception to March 2025 for RCTs comparing onabotulinumtoxinA with placebo in adults with PP. Two reviewers independently extracted data and assessed bias using the Cochrane RoB 2.0 tool. The primary outcomes were ≥ 1-grade and ≥ 2-grade improvement on the Clinician (C-APPS) and Participant (P-APPS) Allergan Platysma Prominence Scales. Secondary outcomes included patient satisfaction and treatment-emergent adverse events (TEAEs). Random-effects meta-analysis was used to estimate pooled risk ratios (RRs) with 95% confidence intervals (CIs). RESULTS: Three RCTs (n = 912) were included. OnabotulinumtoxinA significantly increased ≥ 1-grade (RR = 4.11; 95% CI, 3.60-4.69) and ≥ 2-grade (RR = 1.83; 95% CI, 1.54-2.17) improvements compared to placebo. Patient satisfaction was higher in the treatment group (RR = 5.55; 95% CI, 4.15-7.43). The incidence of TEAEs was similar between groups (RR = 0.95; 95% CI, 0.76-1.20), with most being mild and transient. CONCLUSIONS: OnabotulinumtoxinA is an effective and well-tolerated minimally invasive option for improving platysma prominence, offering significant aesthetic and patient-reported benefits without increasing adverse effects.